Home › Funds › BAKER BROS. ADVISORS LP › GENB
BAKER BROS. ADVISORS LP position in GENB
GENERATE BIOMEDICINES INC · Health Care
BAKER BROS. ADVISORS LP reported holding 1,423,602 shares of GENB (GENERATE BIOMEDICINES INC) in its Q3 2026 13F filing — a position valued at US$21.4M, representing 0.10% of its reported portfolio and ranking #46 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed GENB holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's GENB position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in GENB in Q1 2026 at 1,423,602 shares (US$17.8M). The position peaked in Q2 2026 at 1,423,602 shares, worth US$24.0M. Across 3 filings, BAKER BROS. ADVISORS LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,423,602 shares valued at US$21.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.42M | $17.80M | New |
| Q2 2026 | 1.42M | $24.02M | Hold |
| Q3 2026 | 1.42M | $21.38M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GENB and 13F data
GENB (GENERATE BIOMEDICINES INC) is a Health Care company. 113 other funds we track also report a position in GENB — the largest reported positions include Flagship Pioneering, LLC (US$941.4M), BRAIDWELL LP (US$44.5M), Deep Track Capital, LP (US$37.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GENB
- Flagship Pioneering, LLC 62.67M sh · $941.35M · Q3 2026
- BRAIDWELL LP 2.96M sh · $44.49M · Q3 2026
- Deep Track Capital, LP 2.51M sh · $37.66M · Q3 2026
- ARCH Venture Management, LLC 1.94M sh · $29.21M · Q3 2026
- BANQUE PICTET & CIE SA 1.77M sh · $26.63M · Q3 2026
- HARBOURVEST PARTNERS LLC 1.72M sh · $25.87M · Q3 2026
- Harvard Management Company 1.11M sh · $18.74M · Q2 2026
- ArrowMark Colorado Holdings LLC 1.11M sh · $16.69M · Q3 2026
- NVIDIA CORP 833.33K sh · $12.52M · Q3 2026
- Davern Capital Partners, LP 824.68K sh · $12.39M · Q3 2026
- Prosight Management, LP 144.76K sh · $2.17M · Q3 2026
- PICTET BANK & TRUST Ltd 16.67K sh · $250.32K · Q3 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held GENB?
BAKER BROS. ADVISORS LP has disclosed GENB holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is BAKER BROS. ADVISORS LP's current position in GENB?
As of Q3 2026, BAKER BROS. ADVISORS LP holds 1.42M shares of GENB (GENERATE BIOMEDICINES INC), valued at $21.38M, representing 0.10% of its reported portfolio and ranking #46.
Has BAKER BROS. ADVISORS LP been buying or selling GENB?
In the latest 13F filing (Q3 2026), BAKER BROS. ADVISORS LP held unchanged its position in GENB. The position peaked in Q2 2026 at 1.42M shares.
Which other funds hold GENB?
Other major institutional holders of GENB include Flagship Pioneering, LLC, BRAIDWELL LP, Deep Track Capital, LP, among 113 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.